Sun Pharma Advanced Research Company Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 21, 2025, 7:30 am

Quick Insight

Sun Pharma Advanced Research Company Ltd's current market cap stands at ₹4,607 Cr., with a share price of ₹142. The company's financial health appears concerning, with negative operating profit margin at -198% and net profit at -345. However, the high ROCE of 298% indicates strong capital efficiency. The substantial promoter holding of 65.68% offers stability, though institutional ownership is relatively low. With a negative P/BV of -22.14x and ICR of -35.55x, investors should approach cautiously due to high leverage and poor valuation metrics. In conclusion, while the company shows potential for efficient capital utilization, the negative profitability and high debt levels warrant careful monitoring for future performance.

Competitors of Sun Pharma Advanced Research Company Ltd

All Competitor Stocks of Sun Pharma Advanced Research Company Ltd

Quarterly Result

Last Updated: August 20, 2025, 3:00 am

Below is a detailed analysis of the quarterly data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 17.00 Cr..
• For Expenses, as of Jun 2025, the value is 62.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 81.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 19.00 Cr..
• For Operating Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -54.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 2.00 Cr..
• For OPM %, as of Jun 2025, the value is -543.00%. The value appears to be declining and may need further review. It has decreased from -198.00% (Mar 2025) to -543.00%, marking a decrease of 345.00%.
• For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 9.00 Cr..
• For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -61.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 9.00 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
• For Net Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -61.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 9.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -1.60. The value appears strong and on an upward trend. It has increased from -1.88 (Mar 2025) to -1.60, marking an increase of 0.28.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:55 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:16 pm

Below is a detailed analysis of the balance sheet data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 32.00 Cr..
• For Reserves, as of Mar 2025, the value is -253.00 Cr.. The value appears to be declining and may need further review. It has decreased from 92.00 Cr. (Mar 2024) to -253.00 Cr., marking a decrease of 345.00 Cr..
• For Borrowings, as of Mar 2025, the value is 265.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 56.00 Cr. (Mar 2024) to 265.00 Cr., marking an increase of 209.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 284.00 Cr.. The value appears to be improving (decreasing). It has decreased from 305.00 Cr. (Mar 2024) to 284.00 Cr., marking a decrease of 21.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 329.00 Cr.. The value appears to be improving (decreasing). It has decreased from 486.00 Cr. (Mar 2024) to 329.00 Cr., marking a decrease of 157.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 103.00 Cr. (Mar 2024) to 95.00 Cr., marking a decrease of 8.00 Cr..
• For CWIP, as of Mar 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2024) to 54.00 Cr., marking an increase of 10.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 179.00 Cr.. The value appears to be declining and may need further review. It has decreased from 338.00 Cr. (Mar 2024) to 179.00 Cr., marking a decrease of 159.00 Cr..
• For Total Assets, as of Mar 2025, the value is 329.00 Cr.. The value appears to be declining and may need further review. It has decreased from 486.00 Cr. (Mar 2024) to 329.00 Cr., marking a decrease of 157.00 Cr..

However, the Borrowings (265.00 Cr.) are higher than the Reserves (-253.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Sun Pharma Advanced Research Company Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
• For Diluted EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
• For Cash EPS (Rs.), as of Mar 25, the value is -10.17. This value is below the healthy minimum of 3. It has increased from -11.55 (Mar 24) to -10.17, marking an increase of 1.38.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.69. It has decreased from 3.88 (Mar 24) to -6.69, marking a decrease of 10.57.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.69. It has decreased from 3.88 (Mar 24) to -6.69, marking a decrease of 10.57.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.21. It has decreased from 2.33 (Mar 24) to 2.21, marking a decrease of 0.12.
• For PBDIT / Share (Rs.), as of Mar 25, the value is -9.90. This value is below the healthy minimum of 2. It has increased from -11.48 (Mar 24) to -9.90, marking an increase of 1.58.
• For PBIT / Share (Rs.), as of Mar 25, the value is -10.28. This value is below the healthy minimum of 0. It has increased from -11.87 (Mar 24) to -10.28, marking an increase of 1.59.
• For PBT / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 0. It has increased from -11.92 (Mar 24) to -10.56, marking an increase of 1.36.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.56, marking an increase of 1.37.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.56, marking an increase of 1.37.
• For PBDIT Margin (%), as of Mar 25, the value is -447.74. This value is below the healthy minimum of 10. It has increased from -493.24 (Mar 24) to -447.74, marking an increase of 45.50.
• For PBIT Margin (%), as of Mar 25, the value is -465.01. This value is below the healthy minimum of 10. It has increased from -509.80 (Mar 24) to -465.01, marking an increase of 44.79.
• For PBT Margin (%), as of Mar 25, the value is -477.60. This value is below the healthy minimum of 10. It has increased from -512.05 (Mar 24) to -477.60, marking an increase of 34.45.
• For Net Profit Margin (%), as of Mar 25, the value is -477.23. This value is below the healthy minimum of 5. It has increased from -512.55 (Mar 24) to -477.23, marking an increase of 35.32.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -477.23. This value is below the healthy minimum of 8. It has increased from -512.55 (Mar 24) to -477.23, marking an increase of 35.32.
• For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -307.91 (Mar 24) to 0.00, marking an increase of 307.91.
• For Return on Capital Employeed (%), as of Mar 25, the value is 862.15. This value is within the healthy range. It has increased from -154.06 (Mar 24) to 862.15, marking an increase of 1,016.21.
• For Return On Assets (%), as of Mar 25, the value is -102.08. This value is below the healthy minimum of 5. It has decreased from -75.18 (Mar 24) to -102.08, marking a decrease of 26.90.
• For Long Term Debt / Equity (X), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 0.2. It has decreased from 0.00 (Mar 24) to -0.46, marking a decrease of 0.46.
• For Total Debt / Equity (X), as of Mar 25, the value is -1.19. This value is within the healthy range. It has decreased from 0.37 (Mar 24) to -1.19, marking a decrease of 1.56.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.16. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.06, marking a decrease of 0.96.
• For Quick Ratio (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.06, marking a decrease of 0.96.
• For Interest Coverage Ratio (X), as of Mar 25, the value is -35.55. This value is below the healthy minimum of 3. It has increased from -219.89 (Mar 24) to -35.55, marking an increase of 184.34.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -36.89. This value is below the healthy minimum of 3. It has increased from -227.50 (Mar 24) to -36.89, marking an increase of 190.61.
• For Enterprise Value (Cr.), as of Mar 25, the value is 5,058.83. It has decreased from 11,897.66 (Mar 24) to 5,058.83, marking a decrease of 6,838.83.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 70.49. This value exceeds the healthy maximum of 3. It has decreased from 157.49 (Mar 24) to 70.49, marking a decrease of 87.00.
• For EV / EBITDA (X), as of Mar 25, the value is -15.74. This value is below the healthy minimum of 5. It has increased from -31.93 (Mar 24) to -15.74, marking an increase of 16.19.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 66.92. This value exceeds the healthy maximum of 3. It has decreased from 158.92 (Mar 24) to 66.92, marking a decrease of 92.00.
• For Price / BV (X), as of Mar 25, the value is -22.14. This value is below the healthy minimum of 1. It has decreased from 95.47 (Mar 24) to -22.14, marking a decrease of 117.61.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 66.92. This value exceeds the healthy maximum of 3. It has decreased from 158.93 (Mar 24) to 66.92, marking a decrease of 92.01.
• For EarningsYield, as of Mar 25, the value is -0.07. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.07, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness